Biotech Values

[DewDiligence]

AZN’s gout drug from RDEA misses key secondary endpoints, while hitting on the primary:

http://www.businesswire.com/news/home/20141116005007/en/AstraZeneca-Presents-Data-Phase-III-Studies-Lesinurad#.VGjtHIcwTyx

AstraZeneca today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol. The results show that approximately twice as many patients met the primary endpoint with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0 mg/dL at month 6, compared to those treated with allopurinol alone.

…Among the key secondary endpoints of mean gout flare rates and patients with complete tophus resolution, no significant differences were observed for mean gout flare rates (end of Month 6 to 12) or patients with complete tophus resolution.

AZN acquired Ardea Biosciences in 2012 for $1.26B (#msg-74706626).